YS Biopharma Co., Ltd. (YS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
773
First IPO Date
August 05, 2021
| Name | Title | Pay | Year Born |
| Dave Chenn | Co-Chief Executive Officer | 0 | N/A |
| Hui Shao | Co-Chief Executive Officer, President, Chief Business Officer & Executive Director | 0 | 1968 |
| Gang Li | Head of Marketing & Sales | 0 | 1982 |
| Chunyuan Wu | Chief Financial Officer & Director | 0 | 1978 |
| Yuan Liu | Head of Vaccine Research | 0 | 1987 |
| Zenaida Reynoso Mojares | Chief Medical Officer | 0 | 1959 |
YS Biopharma Co., Ltd., a biopharmaceutical firm established in Beijing, China, in 2002, specializes in the discovery, development, production, and commercialization of vaccines and therapeutic biologics. Their primary focus is on addressing infectious diseases and cancer. Central to their efforts is a proprietary PIKA immunomodulating technology platform, which supports the creation of preventive and therapeutic biologics for conditions such as Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. The company extends its operations across multiple countries, including China, the United States, Singapore, the United Arab Emirates, and the Philippines.